𧬠Acurx Completes Phase 2b Antibiotic Trial
@acurxpharma (NASDAQ: ACXP) has completed its Phase 2b clinical trial of ibezapolstat, evaluating the investigational antibiotic against vancomycin, a standard-of-care treatment for Clostridioides difficile infection (CDI). @vincemedia1
Watch the @NewToTheStreet interview hereππ»ππ»ππ»
https://t.co/KATkqrRhVy
ππ» Learn more at https://t.co/UT5YN4pWUu
ππ»Follow @NewToTheStreet for the latest in biotech, innovation, and business updates!
#acurxpharmaceuticals #wellness #health #healthcare #cure #medicine #pharmacy #science #businessupdate #businessnews #business #news #newtothestreet